RAMSAY HEALTH CARE LIMITED (RHC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RHC

RHC - RAMSAY HEALTH CARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 5.01
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

Ramsay Health Care is a private hospital and healthcare services group with operations in Australia, Europe and the UK. It sold its Ramsay Sime Darby Asia joint venture in 2023.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$50.06

27 Aug
2026

6.040

OPEN

$49.50

13.72%

HIGH

$51.10

2,507,712

LOW

$48.64

TARGET
$47.115

+5.87 change from previous day

 -5.9% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . ALC . BMT . DOC . EBO . HLS . IDX . M7T . MPL . MVF . NHF . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
RHC: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 136.2 172.7 xxx
DPS (cps) xxx 91.0 102.6 xxx
EPS Growth xxx 100.0% 26.8% xxx
DPS Growth xxx 13.8% 12.7% xxx
PE Ratio xxx N/A 29.8 xxx
Dividend Yield xxx N/A 2.0% xxx
Div Pay Ratio(%) xxx 66.8% 59.4% xxx

Dividend yield today if purchased 3 years ago: 1.74%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.77

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 09/03 - ex-div 42.50c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx136.2
DPS All xxxxxxxxxxxxxxx91.0
Sales/Revenue xxxxxxxxxxxxxxx18,577.8 M
Book Value Per Share xxxxxxxxxxxxxxx2,043.4
Net Operating Cash Flow xxxxxxxxxxxxxxx1,442.1 M
Net Profit Margin xxxxxxxxxxxxxxx1.77 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx6.62 %
Return on Invested Capital xxxxxxxxxxxxxxx2.07 %
Return on Assets xxxxxxxxxxxxxxx1.49 %
Return on Equity xxxxxxxxxxxxxxx6.60 %
Return on Total Capital xxxxxxxxxxxxxxx5.90 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx502.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx628 M
Long Term Debt xxxxxxxxxxxxxxx10,370 M
Total Debt xxxxxxxxxxxxxxx10,999 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx730 M
Price To Book Value xxxxxxxxxxxxxxx2.15

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx734.2 M
Capex % of Sales xxxxxxxxxxxxxxx3.95 %
Cost of Goods Sold xxxxxxxxxxxxxxx16,805 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx758 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx131 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.1

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

28/08/2026

3

Neutral

$42.90

-14.30%

Key points from investor call: UBS points to a strong improvement in Ramsay Health Care's Australian margins during 2H26, with underlying EBIT margin up around 100bps, helped by procurement savings, improved theatre utilisation and an easier comparable period.

Around 48% of private insurance-linked revenue is now covered by agreements tied to sector-wide indexation metrics, although wage growth of around 5% and an additional -$10m-$15m of IT operating costs are flagged to create FY27 headwinds.

Management expects domestic EBIT to grow even excluding the National Capital acquisition, while the UK outlook is supported by higher NHS tariffs and private-pay activity.

Elysium also improved following capacity reductions and better labour management, while FY27 interest expense for the Wholly Owned Funding Group is expected to rise to $280-300m from around $260m in FY26.

Neutral rated. Target $42.90.

FORECAST
UBS forecasts a full year FY27 dividend of 103.00 cents and EPS of 157.00 cents.
UBS forecasts a full year FY28 dividend of 120.00 cents and EPS of 184.00 cents.

Morgan Stanley

xx/xx/xxxx

5

xxxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

4

xxxxxxxxx xx xxxxxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

25/08/2026

2

Overweight

$47.60

-4.91%

Jarden maintains its Overweight recommendation for Ramsay Health Care with a target price of $47.60 following an upward revision in the United Kingdom's National Health Service net tariff indexation to 1.24% for the 2026/27 period.

The analyst highlights that this adjustment reflects changes to pay awards and a resident doctors deal, providing a positive signal heading into FY27 after funding constraints weighed on group growth throughout FY26.

The broker's estimates indicate potential for margin support in the United Kingdom business compared to previous expectations of flat-to-down margins.
Access Extra Coverage Research History >

RHC STOCK CHART

FNArena News on RHC

1
FNArena Corporate Results Monitor – 27-08-2026

Aug 27 2026 - Australia
2
Australian Broker Call *Extra* Edition – Aug 25, 2026

Aug 25 2026 - Daily Market Reports
3
Rudi’s View: That’s The Way Markets Crumble

Aug 06 2026 - Rudi's View
4
Rudi’s View: Final Preparations For August

Aug 05 2026 - Rudi's View
5
Australian Broker Call *Extra* Edition – Jul 30, 2026

Jul 30 2026 - Daily Market Reports

Latest Healthcare services News

1
Treasure Chest: Beware Aussie Healthcare

Jul 17 2026 - Treasure Chest
2
Major UK Win Highlights Alcidion’s Potential

May 27 2026 - Small Caps
3
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
4
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
5
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
6
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
7
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
8
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
9
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
10
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps